218 related articles for article (PubMed ID: 23940213)
21. Impact of residential area on the management of rheumatoid arthritis patients initiating their first biologic DMARD: Results from the Ontario Best Practices Research Initiative (OBRI).
Movahedi M; Joshi R; Rampakakis E; Thorne C; Cesta A; Sampalis JS; Bombardier C;
Medicine (Baltimore); 2019 May; 98(20):e15517. PubMed ID: 31096451
[TBL] [Abstract][Full Text] [Related]
22. A multi-center, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease control.
Littlejohn G; Roberts L; Arnold M; Bird P; Burnet S; de Jager J; Griffiths H; Nicholls D; Scott J; Zochling J; Tymms KE
Int J Rheum Dis; 2013 Oct; 16(5):532-8. PubMed ID: 24164840
[TBL] [Abstract][Full Text] [Related]
23. Diagnosis and treatment of rheumatoid arthritis in the Emilia Romagna region: a prospective population-based study.
Addimanda O; Marino M; Farina I; Trevisani M; Arrigoni E; Lumetti F; Crescentini F; Sambo P; Bezzi A; Bruschi M; Santilli D; Reta M; Bosi S; Delsante G; Girelli F; Montaguti L; Meliconi R; Sebastiani M; Ferri C; Malavolta N; Govoni M; Trombetti S; De Palma R; Salvarani C
Clin Exp Rheumatol; 2017; 35(2):201-208. PubMed ID: 28134078
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of minimal disease activity in Australian patients with Psoriatic Arthritis: Assessing the outcome of national funding criteria for biologic disease-modifying antirheumatic drug prescribing.
Pontifex EK; Dissanayake K; Bursill D; Gill T
Int J Rheum Dis; 2019 Feb; 22(2):262-268. PubMed ID: 30450819
[TBL] [Abstract][Full Text] [Related]
25. Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries.
Orlewska E; Ancuta I; Anic B; Codrenau C; Damjanov N; Djukic P; Ionescu R; Marinchev L; Nasonov EL; Peets T; Praprotnik S; Rashkov R; Skoupa J; Tlustochowicz W; Tlustochowicz M; Tomsic M; Veldi T; Vojinovic J; Wiland P
Med Sci Monit; 2011 Apr; 17(4):SR1-13. PubMed ID: 21455121
[TBL] [Abstract][Full Text] [Related]
26. Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?
Yen JH
Biomed Pharmacother; 2006 Dec; 60(10):688-92. PubMed ID: 17049202
[TBL] [Abstract][Full Text] [Related]
27. Lower education and living in countries with lower wealth are associated with higher disease activity in rheumatoid arthritis: results from the multinational COMORA study.
Putrik P; Ramiro S; Keszei AP; Hmamouchi I; Dougados M; Uhlig T; Kvien TK; Boonen A
Ann Rheum Dis; 2016 Mar; 75(3):540-6. PubMed ID: 25630346
[TBL] [Abstract][Full Text] [Related]
28. Primary Nonadherence, Associated Clinical Outcomes, and Health Care Resource Use Among Patients with Rheumatoid Arthritis Prescribed Treatment with Injectable Biologic Disease-Modifying Antirheumatic Drugs.
Harnett J; Wiederkehr D; Gerber R; Gruben D; Bourret J; Koenig A
J Manag Care Spec Pharm; 2016 Mar; 22(3):209-18. PubMed ID: 27003550
[TBL] [Abstract][Full Text] [Related]
29. Drug reimbursement and GPs' prescribing decisions: a randomized case-vignette study about the pharmacotherapy of obesity associated with type 2 diabetes: how GPs react to drug reimbursement.
Verger P; Rolland S; Paraponaris A; Bouvenot J; Ventelou B
Fundam Clin Pharmacol; 2010 Aug; 24(4):509-16. PubMed ID: 19840120
[TBL] [Abstract][Full Text] [Related]
30. Singapore Chapter of Rheumatologists Consensus Statement on the Eligibility for Government Subsidy of Biologic Disease Modifying Antirheumatic Agents for Treatment of Rheumatoid Arthritis (RA).
Teng GG; Cheung PP; Lahiri M; Clayton JA; Chew LC; Koh ET; Koh WH; Lau TC; Ng SC; Thong BY; Vasudevan AR; Yoong JK; Leong KH
Ann Acad Med Singap; 2014 Aug; 43(8):400-11. PubMed ID: 25244989
[TBL] [Abstract][Full Text] [Related]
31. Variations and practice in the care of patients with rheumatoid arthritis: quality and cost of care.
DeMaria L; Acelajado MC; Luck J; Ta H; Chernoff D; Florentino J; Peabody JW
J Clin Rheumatol; 2014 Mar; 20(2):79-86. PubMed ID: 24561410
[TBL] [Abstract][Full Text] [Related]
32. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F
Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811
[TBL] [Abstract][Full Text] [Related]
33. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
Ciubotariu E; Gabay C; Finckh A;
J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
[TBL] [Abstract][Full Text] [Related]
34. Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey.
Hamuryudan V; Direskeneli H; Ertenli I; Inanc M; Karaaslan Y; Oksel F; Ozbek S; Pay S; Terzioglu E; Balkan Tezer D; Hacibedel B; Akkoc N
Clin Exp Rheumatol; 2016; 34(6):1033-1037. PubMed ID: 27749224
[TBL] [Abstract][Full Text] [Related]
35. Gain in quality-adjusted life-years in patients with rheumatoid arthritis during 1 year of biological therapy: a prospective study in clinical practice.
Linde L; Sørensen J; Østergaard M; Hetland ML
J Rheumatol; 2013 Sep; 40(9):1479-86. PubMed ID: 23818719
[TBL] [Abstract][Full Text] [Related]
36. Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region.
Kaló Z; Vokó Z; Östör A; Clifton-Brown E; Vasilescu R; Battersby A; Gibson E
J Mark Access Health Policy; 2017; 5(1):1345580. PubMed ID: 28740623
[No Abstract] [Full Text] [Related]
37. Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target?
Lu CY; Williams KM; Day RO
Intern Med J; 2006 Jan; 36(1):19-27. PubMed ID: 16409309
[TBL] [Abstract][Full Text] [Related]
38. Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity.
Tymms K; Zochling J; Scott J; Bird P; Burnet S; de Jager J; Griffiths H; Nicholls D; Roberts L; Arnold M; Littlejohn G
Arthritis Care Res (Hoboken); 2014 Feb; 66(2):190-6. PubMed ID: 23983001
[TBL] [Abstract][Full Text] [Related]
39. Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting.
Meissner B; Trivedi D; You M; Rosenblatt L
J Med Econ; 2014 Apr; 17(4):259-65. PubMed ID: 24575891
[TBL] [Abstract][Full Text] [Related]
40. A review of cost-effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis.
Iannazzo S; De Francesco M; Gomez-Ulloa D; Benucci M
Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):455-68. PubMed ID: 23977974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
